Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers

Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery

(2011) Ruimei Yuan et al.   CLINICA CHIMICA ACTA

Effects of the CYP Oxidoreductase Ala503Val Polymorphism on CYP3A Activity In Vivo: A Randomized, Open-Label, Crossover Study in Healthy Chinese Men

(2011) Guoping Yang et al.   CLINICAL THERAPEUTICS

Prevalence of Diabetes among Men and Women in China

(2010) Wenying Yang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19

(2010) Vishal Agrawal et al.   Pharmacogenetics and Genomics

CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients

(2009) Wei Zhang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers

(2009) J. Wen et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test

(2009) Beatrice Oneda et al.   Pharmacogenetics and Genomics

CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

(2008) Yuan Gao et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Different Effects ofSLCO1B1Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide

(2008) Annikka Kalliokoski et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

(2008) Annikka Kalliokoski et al.   Pharmacogenetics and Genomics